Area of research
Surgery · Immunology
Research interest
Research interests include Medicine, Internal medicine, Evolocumab, PCSK9, Lipoprotein(a), and Clinical endpoint.
Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial
Eicosapentaenoic acid, arachidonic acid, and triglyceride levels mediate most of the benefit of icosapent ethyl in REDUCE-IT
Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects ― A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial ―
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial
Lipoprotein(a), PCSK9 Inhibition and cardiovascular risk: Insights from the Fourier trial
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin